EMILIN2

Across TCGA pan-cancer cohorts, EMILIN2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated EMILIN2 data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher EMILIN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EMILIN2 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LUAD are the cancer types where EMILIN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.578	0.924	<.001	67	view →
PDAC	DFS	Tertile	All	0.763	0.926	.001	41	view →
LUAD	OS	Median	II,III,IV	0.337	0.908	.002	18	view →
HNSC	OS	Tertile	II,III,IV	0.941	1.000	.034	1	view →
GBM	OS	Median	All	0.690	0.830	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

EMILIN2–CCRCC (DFS)

Open the CCRCC breakdown →